drugset
Drugs / OHB-607
last change Jul 2026 re-read 3 minutes ago

OHB-607

Protein / enzyme biologic

Developed for
bronchopulmonary dysplasia
Investigated by
OHB Neonatology Ltd.

Trials 1

today NCT03253263 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03253263 May 2019 → Jul 2026 overdue bronchopulmonary dysplasia, intracerebral hemorrhage, retinopathy of prematurity OHB Neonatology Ltd. Recruiting No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2024-05-17 Chiesi Farmaceutici S.p.A. Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants chiesi.com ↗
2024-01-08 Chiesi Farmaceutici S.p.A. Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy chiesi.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as OHB-607 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03253263 ↗
Action Restore “may replenish IGF-1 during this period of deficiency” PMID 41786363 ↗ Mar 2026
Modality Protein / enzyme biologic “OHB-607, a recombinant human IGF-1 combined with its binding protein-3” PMID 41786363 ↗ Mar 2026
Route Intravenous “via continuous intravenous infusion” PMID 41786363 ↗ Mar 2026